Drugmakers eye government money to combat antibiotic resistance

  28 October 2022

Political momentum to create a multibillion-dollar fund to reward developers of new antibiotics is growing in Washington. But it comes too late for Scynexis. With little demand so far for its new drug ibrexafungerp, the pharma company is scaling back promotion, seeking a new partner, exploring other applications, and cutting its workforce. Its product is just the latest in a series of antibiotics and other antimicrobials that have struggled to take off, alongside an even longer list of potential drugs that have not made it beyond the laboratory bench. A public health need for innovative treatments is increasingly being confronted by a reluctance to back products for fear they will be lossmaking.

Further reading: Financial Times
Author(s): Andrew Jack
Smart Innovations  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!